Élise Roy1, Marc-Antoine Nolin2, Issouf Traoré3, Pascale Leclerc4, Helen-Maria Vasiliadis5. 1. Full Professor, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, Quebec; Researcher, Research Chair on Addiction, Université de Sherbrooke, Sherbrooke, Quebec. 2. Graduate Student, Clinical Sciences Program, Université de Sherbrooke, Sherbrooke, Quebec. 3. Research Assistant, Direction des statistiques de santé, Institut de la statistique du Québec, Montreal, Quebec. 4. Public Health Officer, Direction de santé publique de l'agence de la santé et des services sociaux de Montréal, Montreal, Quebec. 5. Associate Professor, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, Quebec; Researcher, Charles LeMoyne Hospital Research Centre, Greenfield Park, Quebec.
Abstract
OBJECTIVE: To determine the prevalence and factors associated with nonmedical use of prescription medication (NMUPM) among adolescents who use drugs (ages 12 to 17 years) in Quebec. METHOD: Secondary data analyses were carried out with data from a 6-month study, namely, the 2010-2011 Quebec Health Survey of High School Students-a large-scale survey that sought to gain a better understanding of the health and well-being of young Quebecers in high school. Bivariate and multivariate logistic regression analyses were conducted to study NMUPM among adolescents who use drugs, according to sociodemographic characteristics, peer characteristics, health indicators (anxiety, depression, or attention-deficit disorder [ADD] with or without hyperactivity), self-competency, family environment, and substance use (alcohol and drug use) factors. RESULTS: Among adolescents who had used drugs in the previous 12 months, 5.4% (95% CI 4.9% to 6.0%) reported NMUPM. Based on multivariate analyses, having an ADD (adjusted odds ratio [AOR] 1.47; 95% CI 1.13 to 1.91), anxiety disorder (AOR 2.14; 95% CI 1.57 to 2.92), low self-esteem (AOR 1.62; 95% CI 1.26 to 2.08), low self-control (AOR 1.95; 95% CI 1.55 to 2.45), low parental supervision (AOR 1.43; 95% CI 1.11 to 1.83), regular alcohol use (AOR 1.72; 95% CI 1.36 to 2.16), and polysubstance use (AOR 4.09; 95% CI 3.06 to 5.48) were associated with increased odds of reporting NMUPM. CONCLUSIONS: The observed prevalence of NMUPM was lower than expected. However, the associations noted with certain mental health disorders and regular or heavy use of other psychoactive substances are troubling. Clinical implications are discussed.
OBJECTIVE: To determine the prevalence and factors associated with nonmedical use of prescription medication (NMUPM) among adolescents who use drugs (ages 12 to 17 years) in Quebec. METHOD: Secondary data analyses were carried out with data from a 6-month study, namely, the 2010-2011 Quebec Health Survey of High School Students-a large-scale survey that sought to gain a better understanding of the health and well-being of young Quebecers in high school. Bivariate and multivariate logistic regression analyses were conducted to study NMUPM among adolescents who use drugs, according to sociodemographic characteristics, peer characteristics, health indicators (anxiety, depression, or attention-deficit disorder [ADD] with or without hyperactivity), self-competency, family environment, and substance use (alcohol and drug use) factors. RESULTS: Among adolescents who had used drugs in the previous 12 months, 5.4% (95% CI 4.9% to 6.0%) reported NMUPM. Based on multivariate analyses, having an ADD (adjusted odds ratio [AOR] 1.47; 95% CI 1.13 to 1.91), anxiety disorder (AOR 2.14; 95% CI 1.57 to 2.92), low self-esteem (AOR 1.62; 95% CI 1.26 to 2.08), low self-control (AOR 1.95; 95% CI 1.55 to 2.45), low parental supervision (AOR 1.43; 95% CI 1.11 to 1.83), regular alcohol use (AOR 1.72; 95% CI 1.36 to 2.16), and polysubstance use (AOR 4.09; 95% CI 3.06 to 5.48) were associated with increased odds of reporting NMUPM. CONCLUSIONS: The observed prevalence of NMUPM was lower than expected. However, the associations noted with certain mental health disorders and regular or heavy use of other psychoactive substances are troubling. Clinical implications are discussed.
Authors: Ronald C Kessler; Shelli Avenevoli; E Jane Costello; Katholiki Georgiades; Jennifer Greif Green; Michael J Gruber; Jian-ping He; Doreen Koretz; Katie A McLaughlin; Maria Petukhova; Nancy A Sampson; Alan M Zaslavsky; Kathleen Ries Merikangas Journal: Arch Gen Psychiatry Date: 2011-12-05
Authors: Andres G Viana; Lindsay Trent; Matthew T Tull; Laurie Heiden; John D Damon; Terry L Hight; John Young Journal: Addict Behav Date: 2012-06-24 Impact factor: 3.913
Authors: Rebecca Kate Hodder; Megan Freund; Luke Wolfenden; Jenny Bowman; Karen Gillham; Julia Dray; John Wiggers Journal: BMJ Open Date: 2014-05-26 Impact factor: 2.692
Authors: Jason E Goldstick; Erin E Bonar; Matthew Myers; Amy S B Bohnert; Maureen A Walton; Rebecca M Cunningham Journal: J Stud Alcohol Drugs Date: 2022-01 Impact factor: 2.582
Authors: Katarina M Janicijevic; Sanja S Kocic; Svetlana R Radevic; Mirjana R Jovanovic; Snezana M Radovanovic Journal: Front Pharmacol Date: 2017-06-13 Impact factor: 5.810
Authors: Alexander S Perlmutter; Myrela Bauman; Shivani Mantha; Luis E Segura; Lilian Ghandour; Silvia S Martins Journal: Curr Addict Rep Date: 2018-02-22